跳至主要内容
临床试验/NCT05710081
NCT05710081招募中3 期

Oral Bacterial Lysate to Prevent Persistent Wheeze in Infants After Severe Bronchiolitis; a Randomised Placebo-controlled Trial

Barts & The London NHS Trust1 个研究点 分布在 1 个国家目标入组 894 人开始时间: 2021年11月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
894
试验地点
1
主要终点
Occurrence of parent-reported, healthcare professional-confirmed wheeze between 19 and 24 months after initiation of IMP or placebo.

研究概览

简要总结

The goal of this clinical trial is to learn about the effects of using bacterial lysate in bronchiolitis. The main question it aims to answer are:

Does the use of bacterial lysate after bronchiolitis reduce the likelihood of preschool wheeze

Participants will take either the active medicine or a placebo for 24 months.

详细描述

To establish whether there is superiority of oral BV (broncho vaxom) over placebo in the prevention of parent-reported, healthcare professional-confirmed, persistent wheeze between 19 and 24 months post initiation of IMP/placebo, after a hospital admission for severe bronchiolitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
2 Weeks 至 12 Months(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Intervention

Active Comparator

Bacterial Lysate - Broncho-Vaxom (OM-85) 3.5mg granules once daily for 10 days per month for 24 months

干预措施: Bacterial Lysate (Biological)

Placebo

Placebo Comparator

Placebo - 3.5mg granules once daily for 10 days per month for 24 months

干预措施: Placebo (Drug)

结局指标

主要结局

Occurrence of parent-reported, healthcare professional-confirmed wheeze between 19 and 24 months after initiation of IMP or placebo.

时间窗: 24 months

Occurrence of parent-reported, healthcare professional-confirmed wheeze between 19 and 24 months after initiation of IMP or placebo.

次要结局

  • Use of medication(24 months)
  • Asthma or Wheeze Diagnosis(24 months)
  • Unscheduled Medical attendances(24 months)
  • Number of courses of oral steroids(24 months)
  • Montelukast use(24 months)
  • Number of courses of antibiotics(24 months)
  • Eczema diagnosis(24 months)
  • Safety and Tolerability(24 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验